This acquisition combines Kashiv’s extensive expertise in the development and manufacturing of biosimilars with Amneal’s scale and commercialization capabilities. Kashiv is headquartered in Piscataway, New Jersey with operations in the U.S. and India. Amneal is headquartered in Bridgewater, New Jersey, and is a leading biopharmaceutical company with one of the largest affordable medicine businesses in the U.S.

Together, the companies will establish a fully integrated biosimilar platform at scale, to deliver high-quality, affordable therapies, expand patient access, and strengthen their position in the global biopharmaceutical landscape.

“We are thrilled to combine Kashiv’s highly complementary portfolio and capabilities with Amneal at this critical inflection point for the biosimilar market, particularly in the U.S.,” said Dr. Sandeep Athalye, Chief Executive Officer at Kashiv. “Our companies share a deep-rooted commitment to high-quality, complex medicines, and this transaction builds on the meaningful work we have accomplished through our partnership of more than ten years. We look forward to building on our proven track record of product approvals and advancing our biosimilars pipeline as we work together to expand patient access to life-changing therapies.”

“As biosimilar adoption accelerates and the industry enters an unprecedented period of biologic loss of exclusivity, we see a compelling opportunity to establish leadership and scale in a rapidly expanding market,” said Chirag Patel, Co-Founder and Co-Chief Executive Officer of Amneal. “With Kashiv, Amneal becomes a fully integrated global biosimilars leader at the forefront of the next wave of U.S. affordable medicines. This acquisition is a natural next step in our strategy to build a leading, diversified biopharmaceutical company, and we are confident it will drive accelerated growth and long-term value creation.”

“This acquisition establishes Amneal as a fully integrated global biosimilar platform at scale,” said Chintu Patel, Co-Founder and Co-Chief Executive Officer of Amneal. “By combining Kashiv’s deep R & D and manufacturing capabilities with our commercial strength, we are creating a differentiated platform well-positioned to deliver a strong and consistent cadence of biosimilar launches going forward. Together, we will expand access to high-quality, affordable biologic medicines for patients while driving long-term growth.”

J.P. Morgan is serving as Kashiv’s financial advisor for the transaction, Holland & Knight LLP is serving as legal counsel, and Dhinal Shah Associates is serving as India legal counsel.

About Kashiv BioSciences

Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv BioSciences, LLC in the U.S., together with its subsidiaries in India (collectively, “Kashiv BioSciences”) operates with robust infrastructure and highly skilled teams that provide global R & D, clinical, manufacturing, regulatory, and IP capabilities. We believe our people, partners, and shared purpose fuel our work to advance patient care and access to important medicines. For additional information, please visit kashivbiosciences.com and follow us on LinkedIn.

About Amneal

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.

The post Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader first appeared on M&A Critique.

“(This deal) allows us to build into a new market on the other side of the world that happens to be the second strongest mining resource market in the world. So it is such a strong, natural fit for us,” TMX CEO John McKenzie said in an interview, referring to Australia’s position in the global mining industry.

The acquisition, which encompasses the Cboe Australia and Cboe Canada exchanges, is designed to accelerate TMX’s expansion into high-growth segments including digital assets, derivatives, and prediction markets. According to company data, Cboe’s units in these two regions produced roughly $87 million in revenue throughout 2025, yielding adjusted EBITDA of approximately $25 million.

TMX Chief Financial Officer David Arnold informed market analysts on Wednesday morning that the transaction is expected to be funded through a mix of available cash and new debt.

For Cboe, the divestiture represents a major milestone in a strategic reorganization first disclosed last October. At that time, the firm initiated a comprehensive portfolio assessment that included the potential sale of these specific international units. This follows Cboe’s decision in July of last year to exit its Japanese equities business, a move prompted by shifting market conditions that impacted the local operation’s financial viability.

Cboe CEO Craig Donohue stated that this deal permits the organization to redirect capital and specialized resources toward its primary business lines. This focus is intended to bolster long-term profitability while the company explores emerging industry opportunities.

The deal remains subject to standard closing requirements and regulatory reviews. TMX expects the acquisitions of the Canadian and Australian entities to conclude individually as specific approvals are granted.

“It did create a competitive process in terms of a lot of players that showed interest in the assets, but it also allowed us to have kind of advanced discussions with regulatory bodies, both in Canada and Australia,” he said.

Canaccord Genuity and Macquarie Capital provided financial advice to TMX, while Barclays served as Cboe’s advisor. Legal representation included Sidley Austin and Baker McKenzie.

In February, TMX’s CEO said the IPO pipeline in Canada remains strong with about 1,600 companies at varying stages to list.

Canada’s strength in the mining sector and strong commodity prices have kept IPO interest high, with listings expected to rebound after only two new companies entering the TSX in Toronto last year, CEO John McKenzie had said.

He also said up to half of the 1,600 companies are from outside Canada, with many attracted to TMX’s venture ecosystem that allows early-stage companies to raise capital.

The exchange has actively courted potential listings overseas, McKenzie said.

“We have been engaged in the Middle East. That’s an area that is actually transitioning to more of a mining economy … We have resources that are on the ground in multiple jurisdictions, like South America, like Australia, good resource economies,” McKenzie said.

The post TMX Group to acquire Cboe Global’s Australian and Canadian operations for $300 million first appeared on M&A Critique.

The Japanese government has asked Asian private equity fund ‌MBK Partners to halt its acquisition of machine tools maker Makino Milling Machine, citing national security concerns, in only the second such case to date.

After examining the impact on the production base and the possibility of sensitive technology leaking, the industry ministry “determined that the investment poses a risk of undermining national security”, Finance Minister Satsuki Katayama told parliament on Thursday.

“We took into account ​the fact that … Makino is one of the world’s leading manufacturers of machine tools and that its products are widely used by manufacturers of ​Japan’s defence equipment,” she said.

DEAL REJECTED AS JAPAN SEEKS TO BOOST ARMS EXPORTS

Makino’s shares were down 9.4% in afternoon trade ⁠in Tokyo.

MBK announced its plan in June last year to acquire Makino through a 275 billion yen ($1.72 billion) tender offer, but prolonged domestic and overseas regulatory ​reviews had pushed back the expected launch of the tender offer to late June.

The fund said in a statement on Thursday it had presented measures to dispel ​national security concerns and was surprised by the government’s recommendation.

Makino said it was gathering information and that nothing had been decided.

Prime Minister Sanae Takaichi’s government this week unveiled its biggest overhaul of defence export rules in decades, opening the way for exports of warships, missiles and other weapons.

The shift on arms exports affected the Makino decision as defence-related manufacturers become more important to industrial ​strategy, said a person involved in the discussions.

A government official said the rejection of the Makino deal “is not meant to send a message that Japan is ​shutting down foreign investments”.

Makino’s tools, which are used to manufacture high-end components such as aluminium airframes, require permission from the trade ministry for export due to the potential for military ‌use.

REJECTION ‘SETS A ⁠PRECEDENT’

“Once advanced technologies flow overseas, they cannot be recovered, and from a national security standpoint it is understandable that the government chose not to allow the acquisition,” said Arata Kuno, professor of international economics at Asia University in Tokyo.

“It represents an exceptional measure confined to a highly strategic sector and is unlikely to be applied indiscriminately,” he said.

MBK, a North Asia-focused buyout firm headquartered in Seoul, was founded by American-Korean dealmaker Michael Kim. South Korean prosecutors in January sought a warrant to ​arrest Kim on fraud and other charges ​over the sale of supermarket chain ⁠Homeplus, but a Seoul court rejected the request, saying material the prosecutors had submitted was insufficient to justify the charges.

“This event sets a precedent and will increase the ​risk premium for foreign ⁠takeovers of Japanese companies in core business sectors,” wrote Arun George, an analyst who publishes on Smartkarma. “FEFTA approval can no longer be considered low-risk.”

“Japan is seeking to amend the FEFTA, including a CFIUS-type ⁠board to ​deal with these situations more proactively,” said Travis Lundy, an analyst who publishes on Smartkarma, referring ​to the Committee on Foreign Investment in the U.S.

“Perhaps they will find more bids to reject, but so far, one event does not a trend make,” he said.

The post Japan halts MBK’s Makino Milling buyout bid on security concerns first appeared on M&A Critique.

U.S. energy major Exxon Mobil ‌is in talks to sell its Hong Kong fuel stations in a deal that could fetch a few hundred million dollars, said three people with knowledge of the matter.

The company has hired a financial adviser and held discussions ​with a handful of bidders, the sources said on condition of anonymity because the information ​was confidential.

Four to five bidders are involved, including a few trading houses, they ⁠said without disclosing any of the suitors.

The planned sale was first reported on Wednesday by Bloomberg. ​Exxon could value the assets between $500 million and $600 million, the report said, citing unnamed sources.

Exxon did not ​respond immediately to a request for comment.

The deal activity comes against a backdrop of ​Hong Kong’s push towards transport electrification and oil price volatility driven by the Iran war.

Given Exxon’s size and market ‌share ⁠in Hong Kong, the deal is expected to fetch a much higher number than the Chevron sale, one of the sources said.

Exxon provides a variety of products and services to customers in Hong Kong through an extensive network of service stations operating under the Esso brand. Its first Hong Kong service ​station opened in Kowloon ​in 1926. The company ⁠now sells fuel in Hong Kong through a network of about 41 Esso-branded service stations.

The company warned this month that first-quarter earnings could fall from the ​previous quarter after a multibillion-dollar hit from hedging and accounting effects outweighed ​higher oil ⁠and gas prices.

Rival Chevron similarly said stronger upstream earnings from higher crude prices would be offset partly by timing effects tied to hedging.

The Middle East conflict has disrupted flows through the Strait of Hormuz, a key ⁠route for ​global oil shipments, driving sharp price swings and adding uncertainty ​to valuations for fuel-related assets.

The post Exxon Mobil in talks to sell Hong Kong fuel station network, sources say first appeared on M&A Critique.

London-listed specialty insurer Beazley said on Wednesday that shareholders approved Swiss ​group Zurich Insurance’s 8.1 billion pound ($10.94 ‌billion) all-cash takeover, with 99.9% votes in favor at a meeting held earlier in ​the day.

The acquisition, which follows a series of ​cyber-focused investments by Zurich, will help the ⁠Swiss insurer significantly expand its foothold in ​specialty insurance, encompassing areas such as cyber, marine, aviation, ​space and fine art.

Days after Zurich struck the deal with Beazley, it also agreed to buy Generali’s Irish P&C ​operations for 337 million euros ($394.69 million).

Last year, ​it acquired Canadian cyber insurtech Boxx Insurance, after backing ‌the ⁠company in earlier funding rounds. In 2024, it had invested $60 million in California-based Cowbell.

Earlier in March, Zurich raised 3.9 billion Swiss ​francs ($4.98 billion) ​in a ⁠share sale to help finance the Beazley acquisition, after the British insurer ​accepted an improved offer of up ​to ⁠1,335 pence per share.

The transaction remains subject to court sanction, which Beazley said it ⁠expects ​will take place during ​the second-half of 2026.

The post Beazley shareholders approve Zurich’s $10.9 billion cash takeover first appeared on M&A Critique.

British product testing firm Intertek on Wednesday said it is reviewing a sweetened takeover proposal from Swedish ​private equity group EQT AB, valuing it ​at 8.3 billion pounds ($11.22 billion).

EQT is now offering ⁠54 pounds per share in cash, after ​Intertek’s board rejected an earlier 51.50 pound a share bid ​saying it undervalued the firm.

The Financial Times first reported the news of EQT’s improved takeover proposal, which it said ​valued Intertek at 9.7 billion pounds, including debt.

EQT, ​which did not respond to a request for comment, must ‌decide ⁠whether to make a firm offer for Intertek by May 14 or walk away.

Intertek shares rose as much as 5.5% to 51.6 pounds and ​were up 2.2% ​at 1508 ⁠GMT.

Last week, Intertek, which helps companies ensure their products, operations and supply ​chains meet quality, safety and sustainability standards, ​said ⁠it was exploring a split of its two businesses, a move that analysts have since described as “defensive” ⁠following the ​disclosure of EQT’s first takeover ​bid.

The post UK’s Intertek considers EQT’s $11.2 billion sweetened takeover bid first appeared on M&A Critique.

European broadcaster RTL secured unconditional EU antitrust approval for its ​Sky Deutschland acquisition on Wednesday after regulators said ‌the deal would not pose any competition concerns in Europe.

“We looked carefully at this deal, and ultimately found no evidence that this acquisition would raise any competition concerns,” EU antitrust chief Teresa Ribera said in a ​statement.

“The transaction will ​allow well-established ⁠European media groups to consolidate their position at a time when the industry is ​transforming, and they are facing increasing pressure ​from global ⁠streaming platforms,” she said.

Reuters reported last month that the deal would gain early EU antitrust approval.

Ribera is currently revamping ⁠EU ​merger rules to allow European ​companies to scale up when possible so they can challenge U.S. and ​Chinese rivals.

The post RTL wins unconditional EU antitrust approval for Sky Deutschland acquisition first appeared on M&A Critique.

The deal comes amid booming demand for AI chips in recent years ‌as companies ⁠ramp ⁠up spending on data centers and high-performance computing to support generative AI applications, benefiting ​chip firms and equipment makers across the supply chain.

Robust demand has boosted orders ​for advanced chips and the tools used to manufacture them, despite lingering worries over supply constraints and the industry’s cyclical nature.

The deal is ​expected to generate gross proceeds of ⁠up to $342 ‌million, including $242 million held in the special purpose acquisition ​company’s (SPAC) trust ​account.

A SPAC is a shell firm that ⁠raises capital through an IPO to merge with a private ​business, offering a quicker alternative than a traditional ​IPO.

SPAC mergers hit record levels in 2020 and 2021, with several Wall Street heavyweights – including billionaire investors Bill Ackman and Michael Klein – betting on them as the next big trend in listings.

However, activity slowed sharply in subsequent years as regulatory scrutiny increased and investors ‌soured on the once-popular vehicle.

Forge Nano is backed by several marquee investors, including Volkswagen, GM Ventures and LG ​Technology Ventures. It ​has also received a $100 ⁠million grant from the US Department of Energy.

Forge Nano said it will use the proceeds to scale US manufacturing of semiconductor tools and ​lithium-ion batteries and support expansion into high-growth markets such as pharmaceuticals, data centers and quantum computing.

The companies expect the SPAC deal to close in the second-half of 2026. The combined entity will trade on the Nasdaq under the ticker symbol ‘NANO’.

The post AI chipmaker Forge Nano to list via $1.6 billion SPAC deal first appeared on M&A Critique.

Along with OpenAI and Anthropic, Cursor is one of several Silicon Valley ‌startups that ⁠have ⁠drawn waves of developers by using artificial intelligence to automate coding, a business where AI companies have found early commercial traction.

The deal could give xAI, the Grok chatbot maker that SpaceX merged with in February, a stronger foothold in the AI coding market where it has so far lagged rivals. It also provides Cursor with ⁠more computing ‌capacity to develop AI models.

“The combination of Cursor’s leading product and distribution to expert software engineers with SpaceX’s ⁠million H100 equivalent Colossus training supercomputer will allow us to build the world’s most useful models,” SpaceX said in an X post on Tuesday.

Colossus is xAI’s supercomputer cluster in Memphis, which it has touted as the largest in the world. The company has been spending billions of dollars on AI infrastructure.

The announcement comes ahead of SpaceX’s highly anticipated public debut ‌in the coming months, with the company eyeing a valuation of close to $1.75 trillion and a $75 billion fundraise that could go down as ⁠the biggest IPO in history.

Two product engineering heads at Cursor, a startup that sells AI models for coding tasks, said in March they joined SpaceX to contribute to the company’s lunar projects and xAI, Musk’s AI startup that is now part of SpaceX.

Musk welcomed the engineers, Andrew Milich and Jason Ginsberg, saying, “Orbital space centers and mass drivers on the Moon will be incredible.”

The post SpaceX says it has option to acquire startup Cursor for $60 billion first appeared on M&A Critique.

Deutsche Telekom is considering a full combination with T-Mobile US that could result in the largest ​public M&A deal on record, Bloomberg News reported on Tuesday, citing people ‌familiar with the matter.

The German telecoms group has been in talks about creating a new holding company that would make a stock bid for shares of both Deutsche Telekom and T-Mobile, the report said.

Deutsche Telekom ​is the majority shareholder in T-Mobile, with a stake of nearly 53%, according ​to LSEG data.

Shares of T-Mobile, with a market value of about $218.57 ⁠billion, rose more than 1% following the news.

Deutsche Telekom has a valuation of ​about $166.46 billion. In February, the company said it had no plans to sell any ​T-Mobile shares in 2026.

“Deutsche Telekom’s tighter grip on T-Mobile is all about backing ​its strongest asset and building the broader group around that momentum,” said PP ​Foresight analyst Paolo Pescatore.

Discussions are at a preliminary stage and any transaction would require political support to ‌move ⁠ahead, according to the report, which added that details of the potential deal could also change.

Deutsche Telekom and T-Mobile declined to comment when contacted by Reuters. The White House and the Federal Network Agency, the primary regulatory body overseeing telecommunications in Germany, did not ​immediately respond to requests.

The ​German telecoms group ⁠has been the majority owner of the U.S. wireless carrier since buying VoiceStream for $50.7 billion in 2000 and renaming it T-Mobile ​USA. Its stake was diluted after T‑Mobile merged with MetroPCS ​in 2013 ⁠and then Sprint in 2020.

Deutsche Telekom’s shareholders, including the German state and government-controlled bank KfW, both of which own 14%, would have a say in the potential merger.

Deutsche Telekom beat fourth-quarter core ⁠profit ​expectations in February but issued a mixed outlook ​for 2026, while T-Mobile raised its forecast for 2027 service revenue and adjusted free cash flow.

The post Deutsche Telekom exploring merger with T-Mobile, Bloomberg News reports first appeared on M&A Critique.